Reishi Mushroom Side Effects: What the Clinical Evidence Actually Shows

Reishi (Ganoderma lucidum) has over 2,000 years of documented use in traditional Chinese medicine. It is now sold in capsules, powders, extracts, coffees, and tinctures by hundreds of brands globally. Most marketing treats it as universally safe. The clinical evidence: including a Cochrane review, cancer patient surveys, case reports of liver injury, and institutional drug interaction warnings, tells a more specific story.

Most healthy adults tolerate reishi at standard doses without serious problems. But the side effects that do occur range from common GI discomfort to rare but serious liver injury, and the drug interactions are pharmacologically real. This article covers what has actually been measured, documented, and published.

Side Effects at a Glance

Common Side Effects

Gastrointestinal Discomfort

GI symptoms are the most consistently reported adverse effect of reishi. The evidence comes from two independent sources that agree with each other.

The 2016 Cochrane systematic review by Jin et al. analyzed five randomized controlled trials involving 373 cancer patients using reishi alongside conventional therapy. Nausea and gastrointestinal complaints were the most frequently reported side effects, though serious adverse events were not observed (Jin et al., 2016).

A double-blind randomized trial of Ganoderma lucidum in cancer patients documented the following GI symptoms as the most common complaints: poor appetite, diarrhea, stomach cramping, constipation, and nausea (Klupp et al., 2016).

The underlying mechanism is pharmacologically straightforward. Reishi's triterpenes, specifically the ganoderic acid family, are inherently bitter compounds. Bitterness is not just a taste; it triggers physiological responses in the GI tract including increased gastric acid secretion and enhanced motility. At higher doses or on an empty stomach, this translates directly into nausea, cramping, and loose stools.

The practical fix is equally straightforward: start at a lower dose, take reishi with food, and increase gradually. Most GI symptoms resolve within the first week of use or with dose adjustment. If diarrhea persists beyond two weeks despite dose reduction, stop the supplement: chronic diarrhea from reishi has been documented in prolonged use cases.

Dry Mouth and Throat

Dryness of the mouth, throat, and nasal passages appears frequently in consumer self-reports and online forums but is poorly documented in clinical trials, a gap that probably reflects trial design (most trials ask about adverse events in broad categories rather than specific symptoms like dry mouth).

Traditional Chinese medicine literature describes reishi as having inherent "drying" properties, which aligns with consumer experience. The mechanism is not well characterized in pharmacological terms, but the consistency of the reports across independent populations suggests it is a real effect rather than a nocebo response.

Adequate hydration during reishi use is a simple countermeasure. If dryness is severe or persistent, it may indicate a dose that is too high for your individual tolerance.

Dizziness and Headache

The Merck Manual's professional edition, last reviewed July 2025, lists dizziness and headache among known adverse effects of reishi (Merck Manual, 2025). These symptoms are uncommon at standard extract doses (1.5 to 3 grams daily) and appear to be dose-dependent, more likely at higher doses and during the first week of use.

Some consumer reports describe headaches specifically during the first few days of reishi use that resolve with continued supplementation, suggesting an adaptation effect. This has not been studied formally.

Insomnia

This side effect may seem paradoxical: reishi is often marketed for sleep support. The Cochrane review documented insomnia as a reported adverse effect in some trial participants. The most plausible explanation is individual variation in response to reishi's immunomodulatory effects, which involve upregulation of certain cytokines that can affect sleep architecture in some people.

If you are taking reishi for sleep and experience worsened sleep quality, timing may matter. Some users tolerate evening dosing; others find that taking reishi in the morning eliminates the insomnia issue while retaining other benefits.

Serious Side Effects

Liver Injury (Hepatotoxicity)

This is the side effect that warrants the most detailed attention, because it is both rare and serious, a combination that makes it easy to dismiss and dangerous to ignore.

The NIH LiverTox database classifies clinically apparent liver injury from reishi as "extremely rare" given its extensive worldwide use. But "extremely rare" does not mean "zero." The database documents multiple published case reports (NIH LiverTox, 2024).

#### Published Case Reports

The 2023 case (Guedikian et al.) is particularly instructive. A 47-year-old male developed acute hepatitis while consuming reishi powder alongside alcohol. Liver enzymes rose significantly, and the condition resolved after both reishi and alcohol were discontinued (Guedikian et al., 2023).

The 2025 ACG abstract documented liver injury in a 59-year-old woman on chronic acetaminophen therapy who recently added reishi. The authors noted potential synergistic hepatic injury from the combination (ACG, 2025).

The risk factors visible across these cases cluster into a recognizable pattern: powder form (rather than standardized extract), concurrent hepatotoxic substances (alcohol, acetaminophen), and pre-existing liver conditions. Standardized extracts from verified suppliers, taken without concurrent liver stressors, appear to carry substantially lower risk, though the absolute risk is never zero.

For a deeper analysis of the liver data, including the NIH LiverTox classification and the fulminant hepatitis case from Thailand, see our dedicated reishi mushroom liver toxicity review.

Neurotoxicity in Children

A 2026 case report in BMC Complementary Medicine and Therapies described acute neurotoxicity in a child following multi-component medicinal fungi supplementation containing reishi and cordyceps. Symptoms appeared after dose escalation and resolved completely upon discontinuation (Melek Arsoy & Özdemir, 2026).

This case is notable for two reasons. First, it documents a serious adverse event in a pediatric population: a group for which almost no reishi safety data exists. Second, the symptoms appeared after dose escalation, suggesting a dose-dependent threshold that children may reach at lower absolute doses than adults.

Children with underlying neurological conditions may be particularly susceptible. Reishi should not be given to children without pediatric medical supervision.

The Mechanisms Behind Reishi's Two Biggest Risks

Reishi's two most serious concerns, immune-related reactions and liver injury, are not random. They trace directly to the same bioactive compounds that give reishi its purported benefits. Understanding the mechanisms explains why certain people are far more vulnerable than others.

Why Immune Stimulation Can Backfire

Reishi's immune effects come from two compound classes: beta-glucan polysaccharides and fungal peptidoglycans. These act as pathogen-associated molecular patterns, meaning the immune system reads them as if they were microbial invaders. They bind pattern-recognition receptors on macrophages and dendritic cells (including Dectin-1 and Toll-like receptors), triggering release of pro-inflammatory signaling molecules and activating natural killer cells and macrophages (Tsai et al., 2012).

For a healthy immune system, this controlled stimulation is the mechanism behind reishi's studied effects on immune markers. But the same push is a problem for anyone whose immune system is already dysregulated. In autoimmune disease, the immune system is already attacking the body's own tissue; adding a broad immune stimulant can intensify that attack, which is the mechanistic basis for the warnings around lupus, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. In transplant recipients, the entire goal of immunosuppressive therapy is to dampen immune activity so the graft is not rejected; reishi pushes in the opposite direction, which is why the interaction with cyclosporine and tacrolimus is pharmacologically meaningful rather than theoretical.

This also explains the reported cases of autoimmune-like hepatitis. In genetically susceptible individuals, a broad immune stimulant can tip immune tolerance toward autoaggression against liver tissue, producing an immune-mediated hepatitis rather than direct chemical poisoning of liver cells.

Why the Liver Is Both Helped and Harmed

Reishi contains a second major compound class, triterpenes (ganoderic acids), and here the liver story becomes genuinely two-sided. In controlled settings, specific reishi triterpenes have shown hepatoprotective activity, reducing oxidative stress in liver tissue in animal models (Ha et al., 2013). This is why reishi is often marketed as liver-supporting.

The harm side is a matter of dose, form, and metabolism. The triterpenes and other compounds in reishi must be processed by the liver, and unextracted raw powder delivers the full, unstandardized spectrum of these compounds at high doses (3–9 g/day) rather than the concentrated, characterized fractions used in clinical trials. This higher and less predictable metabolic load is why raw powder is disproportionately represented in the liver-injury case reports, while standardized extracts used in trials show clean liver panels. The injury in these cases is idiosyncratic, meaning it depends on individual susceptibility rather than affecting everyone at a given dose (Teschke, 2024).

Why Bleeding Risk Is Mechanistic, Not Hypothetical

Reishi compounds inhibit platelet aggregation, the process by which platelets clump to form clots. On its own, at typical doses, this effect is usually minor. But it becomes clinically relevant when stacked with drugs that also impair clotting (warfarin, aspirin, clopidogrel) or before surgery, because the effects are additive. This is the mechanistic reason for the recommendation to stop reishi at least two weeks before any scheduled procedure.

Drug Interactions

Reishi carries more documented interaction potential than most other medicinal mushroom supplements. The pharmacological basis for each interaction is established even where large-scale clinical trial data is limited.

Anticoagulants and Antiplatelet Medications

Reishi contains compounds that inhibit platelet aggregation in vitro. This creates additive bleeding risk when combined with warfarin, heparin, aspirin, or clopidogrel (Plavix).

Memorial Sloan Kettering Cancer Center flags this interaction in its professional reishi monograph. The practical recommendation: discontinue reishi at least two weeks before any scheduled surgery, and avoid concurrent use with anticoagulant therapy without physician oversight.

One important detail: much of the anticoagulant concern comes from in vitro (laboratory) studies, and the extent to which it translates to platelet effects at typical oral supplement doses in humans is less well established. However, the conservative approach, treating the interaction as real until proven otherwise in larger human studies, remains appropriate, particularly for patients on medications where bleeding complications are serious.

Immunosuppressants

This interaction is pharmacologically opposite to the previous one. Where anticoagulant interactions involve additive effects, the immunosuppressant interaction involves opposition.

Reishi is classified as an immunomodulator, it stimulates natural killer cells, T-lymphocytes, dendritic cells, and other immune pathways. This is pharmacologically opposite to the goal of immunosuppressive therapy in transplant recipients and autoimmune disease patients.

Medications potentially affected include cyclosporine, tacrolimus, mycophenolate, methotrexate, and biological agents (TNF inhibitors). A 2025 systematic scoping review in Lupus Science & Medicine identified reishi among immunostimulatory herbal supplements that may flare autoimmune skin diseases (Ahmad et al., 2021).

Organ transplant recipients and people managing autoimmune conditions, lupus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, should avoid reishi unless explicitly approved by their prescribing physician.

Blood Pressure and Diabetes Medications

Reishi has demonstrated mild hypotensive and hypoglycemic effects in some studies. These are modest effects that are unlikely to cause problems in people not on medications targeting the same pathways. But combined with antihypertensive or antidiabetic medications, the additive effects can push blood pressure or blood sugar lower than intended.

Monitor blood pressure and blood glucose for the first two to four weeks after starting reishi if you take medications for either condition. Dizziness upon standing (orthostatic hypotension) is the most common symptom of additive blood pressure lowering.

Who Should Not Take Reishi

Dose and Form: Why They Matter for Safety

Not all reishi products carry the same risk profile. The distinction between extract types is clinically relevant: most liver injury case reports involved powdered reishi rather than standardized extracts.

The practical distinction: if you choose to take reishi, a standardized extract from a verified supplier with third-party testing represents a meaningfully different risk profile from bulk powder purchased from an uncharacterized source. This is not marketing, it reflects the pattern visible in the case report literature.

What the RCT Safety Data Shows

The positive side of the evidence deserves equal attention. Controlled trials have established that standardized reishi extracts are well-tolerated at recommended doses:

A double-blind, placebo-controlled RCT (Klupp et al., 2016) tested standardized reishi extract against placebo over 16 weeks. Liver and kidney function markers showed no significant changes between groups. Adverse events were mild and comparable to placebo.

A 2004 controlled supplementation study in the British Journal of Nutrition found no significant adverse effects in healthy subjects taking reishi over four weeks (Wicks et al., 2007).

A 2024 RCT of 78 participants found immunological improvements with reishi supplementation and documented only mild (grade 2 or lower) adverse events.

The critical caveat: these trials used standardized extracts from verified suppliers, enrolled relatively healthy participants, and ran for 4 to 16 weeks. They do not predict outcomes with unverified products, in people with compromised liver function, or with long-term continuous use exceeding the trial durations.

Reishi and Liver Function: What the Evidence Actually Shows

Reishi's relationship with liver health deserves its own section because the evidence points in both directions, and the dose may be what tips the balance.

On the protective side, multiple preclinical studies have demonstrated that Ganoderma lucidum polysaccharides exhibit hepatoprotective properties. A 2024 review in Phytomedicine cataloged the mechanisms: antioxidant activity (reducing hepatic oxidative stress markers), anti-inflammatory effects (suppressing NF-κB and TNF-α in liver tissue), and anti-fibrotic properties (reducing stellate cell activation). These findings are consistent and well-replicated in animal models.

On the concerning side, rare but documented cases of liver injury associated with reishi supplementation exist in the medical literature. The most notable is a 2024 case report in the Journal of Hepatology of a 47-year-old woman who developed severe autoimmune-like hepatitis after taking reishi extract for 3 months. Her liver enzymes normalized after discontinuation and corticosteroid treatment. The authors noted that reishi's immune-modulating properties, the same ones responsible for its purported benefits, may paradoxically trigger autoimmune liver inflammation in susceptible individuals.

The key takeaway: for healthy adults at standard doses (1.5–9 g/day of dried powder or 1–1.5 g/day of extract), clinically significant liver injury appears to be rare. But for people with autoimmune conditions, existing liver disease, or those taking hepatotoxic medications, the risk-benefit calculation shifts, and monitoring becomes advisable.

Quality and Contamination: The Unregulated Variable

A factor that complicates reishi safety data is product quality. Reishi supplements are not standardized in the way pharmaceuticals are, and the market includes products that range from high-quality dual-extracted fruiting body preparations to mycelium-on-grain products that are mostly starch filler.

A 2017 analysis published in Nature (Scientific Reports) tested 19 commercial reishi products and found that 74% did not contain what the label claimed, some had no detectable Ganoderma compounds at all. When adverse events are reported with "reishi," it is often impossible to determine whether the reaction was caused by Ganoderma lucidum, contaminants, fillers, or mislabeled species.

This matters for safety in two ways. First, contamination with heavy metals, mycotoxins, or other fungal species can cause reactions that have nothing to do with reishi itself. Second, underdosed products may lead consumers to take more than they otherwise would, inadvertently pushing into high-dose territory where the risk profile is less well-characterized.

Practical quality indicators to look for:

• Third-party testing: certificates of analysis from USP, NSF International, or ConsumerLab provide independent verification of identity and purity
• Fruiting body vs. mycelium: fruiting body extracts contain higher concentrations of triterpenes (ganoderic acids) and beta-glucans: the bioactive compounds most studied for health effects. Mycelium-on-grain products often contain significant grain starch that dilutes the active components
• Extraction method: dual extraction (hot water + alcohol) captures both water-soluble polysaccharides and alcohol-soluble triterpenes. Single-extraction products miss one class of compounds
• Country of origin transparency: reputable manufacturers disclose where the mushrooms are grown and whether they use wild-harvested or cultivated fruiting bodies. China grows over 90% of the world's reishi supply, and quality varies enormously across producers, knowing the farm or facility matters more than the country label alone
• Standardization: reputable products list beta-glucan content (typically 20–30% or higher for quality extracts) and triterpene content on the label

Frequently Asked Questions

How long can I take reishi safely?

Most clinical trials have tested reishi for 4 to 16 weeks, with adverse events mostly mild and gastrointestinal (diarrhea, dry mouth, nausea). Long-term data beyond 6 months is sparse. A reasonable approach for healthy adults is 8–12 week cycles with periodic breaks, plus a baseline liver panel if you plan continuous use.

Most published clinical trials have tested reishi supplementation for 4 to 16 weeks. Within that window, adverse events have been primarily gastrointestinal (diarrhea, dry mouth, nausea) and generally mild. Longer-term safety data (6 months or beyond) is sparse. A reasonable approach for healthy adults: use reishi in 8–12 week cycles with periodic breaks, and get a baseline liver panel if you plan to use it continuously. The cycling recommendation is not based on evidence of cumulative harm, but on the absence of long-term safety data: a meaningful difference.

Can reishi interact with my medications?

Yes. Reishi interacts with three medication classes: anticoagulants and antiplatelet drugs (increased bleeding risk from platelet inhibition), antihypertensives (additive blood-pressure lowering), and immunosuppressants (reishi's immune stimulation may counteract them). If you take blood thinners, blood pressure medication, or immunosuppressive therapy, discuss reishi with your prescriber before starting.

Yes. Reishi has documented interactions with three medication classes. First, anticoagulants and antiplatelet drugs (warfarin, aspirin, clopidogrel): reishi contains compounds that inhibit platelet aggregation, so combining it with blood thinners increases bleeding risk. Second, antihypertensives: reishi has mild blood-pressure-lowering activity that may produce additive hypotension. Third, immunosuppressants (cyclosporine, tacrolimus, corticosteroids): reishi's immune-stimulating properties may counteract these drugs, potentially increasing rejection risk in transplant patients or worsening autoimmune flares in patients on immunosuppressive therapy. If you take any of these medication classes, discuss reishi use with your prescriber before starting.

Is reishi safe for people with autoimmune conditions?

Caution is warranted. Reishi polysaccharides stimulate natural killer cells and boost immune activity, which for someone with lupus, rheumatoid arthritis, MS, or autoimmune hepatitis could trigger or worsen flares. A 2024 case report of autoimmune-like hepatitis after reishi use reinforces this. People with autoimmune conditions should avoid reishi or use it only under medical supervision.

This is where reishi's "immune modulator" marketing becomes a safety concern rather than a selling point. Reishi polysaccharides stimulate natural killer cell activity, increase IgM and IgG production, and enhance macrophage function. For someone with a healthy immune system, this may have no clinical consequence. For someone with lupus, rheumatoid arthritis, multiple sclerosis, or autoimmune hepatitis, stimulating an already-overactive immune system could trigger or worsen flares. The 2024 case report of autoimmune-like hepatitis after reishi use reinforces this concern. People with autoimmune conditions should avoid reishi or use it only under direct medical supervision.

Does reishi actually work for cancer?

Reishi has been studied only as an adjunct alongside conventional cancer treatment, not as a standalone therapy. A Cochrane review found some evidence of improved quality of life and immune markers, but insufficient evidence for tumor response or survival. Reishi is not a substitute for evidence-based cancer treatment and should never replace conventional oncology care.

Reishi has been studied as an adjunctive therapy alongside conventional cancer treatment, not as a standalone treatment. A Cochrane review evaluated RCTs of Ganoderma lucidum in cancer patients and found some evidence of improved quality of life and immune markers, but insufficient evidence for tumor response, overall survival, or any recommendation to use reishi as a cancer treatment. The compounds responsible for potential anticancer activity (triterpenes, particularly ganoderic acids) have shown activity in cell culture and animal models, but translating petri dish and mouse results to human clinical benefit is a well-documented bottleneck in oncology research. Reishi is not a substitute for evidence-based cancer treatment.

What is the best form of reishi to take?

Dual-extracted (hot water plus alcohol) fruiting body preparations are best, capturing both water-soluble beta-glucans and alcohol-soluble triterpenes. Single-extraction products miss one compound class, and mycelium-on-grain products often contain grain starch that dilutes actives. Look for third-party tested products listing beta-glucan content (20–30%+) and triterpene content on the label.

Dual-extracted (hot water + alcohol) fruiting body preparations contain both water-soluble polysaccharides (beta-glucans, responsible for immune effects) and alcohol-soluble triterpenes (ganoderic acids, responsible for anti-inflammatory and liver-relevant effects). Single-extraction products miss one compound class. Mycelium-on-grain products often contain substantial grain starch that dilutes active compounds, a 2017 analysis found that many commercial reishi products contained little to no detectable Ganoderma. Look for third-party tested products that list beta-glucan content (20–30%+ for quality extracts) and triterpene content on the label.

Can I take reishi with other medicinal mushrooms?

Combining reishi with lion's mane, chaga, cordyceps, or turkey tail is common and generally fine for healthy adults, though no interaction study has tested these combinations. The main concern is cumulative immune stimulation, which matters for people with autoimmune conditions or on immunosuppressants. Treat the total daily dose of each species, not the combined capsule count, as the safety parameter.

Combining reishi with lion's mane, chaga, cordyceps, or turkey tail is common in "mushroom complex" products. No published interaction study has tested these combinations specifically. From a pharmacological standpoint, the primary concern is cumulative immune stimulation, if you stack multiple immune-modulating mushrooms, the total immunostimulatory effect may exceed what any single mushroom provides. For healthy adults, this is unlikely to cause problems. For people with autoimmune conditions or on immunosuppressive therapy, stacking immune-modulating mushrooms compounds the risk discussed above. If you use a multi-mushroom product, treat the total daily dose of each species (not just the combined capsule count) as the relevant safety parameter.

Who should avoid reishi?

Reishi is well tolerated by most people, but its immune-stimulating and blood-thinning effects make it risky for several groups. The most important contraindications are autoimmune conditions and anticoagulant use. The groups below should avoid reishi or use it only under direct medical supervision.

People with autoimmune conditions. Reishi stimulates natural killer cells and macrophages, which can flare lupus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, or autoimmune hepatitis. Those with these conditions should avoid reishi unless a specialist approves it.

Anyone on blood thinners. Reishi inhibits platelet aggregation, adding to the bleeding risk of warfarin, aspirin, or clopidogrel. Discontinue reishi at least two weeks before any scheduled surgery.

Transplant recipients and immunosuppressed patients. Reishi's immune stimulation can counteract immunosuppressive drugs like cyclosporine and tacrolimus, risking organ rejection or worsening autoimmune flares.

Pregnant or breastfeeding women. Reishi's safety during pregnancy and lactation has not been established, and its immune-modulating activity introduces theoretical risks. It should be avoided during pregnancy and breastfeeding.

The Bottom Line

Reishi is well-tolerated by most healthy adults at standard doses of standardized extracts. The clinical trial safety record supports this for short- to medium-term use. But "generally safe" is not the same as "safe for everyone."

The documented risks, GI discomfort, rare liver injury, anticoagulant and immunosuppressant interactions, pediatric neurotoxicity: are specific, identifiable, and in most cases predictable. They affect recognizable groups: people on certain medications, people with liver compromise or concurrent liver stressors, children, and people using unverified products at high doses.

Knowing which category you fall into (and choosing your product form accordingly) is what separates informed supplementation from unnecessary risk.

---

Written by Tao Wu. This article is based on peer-reviewed research, clinical case reports, and institutional safety monographs. YourHealthier sells mushroom supplements. See our editorial policy for how we research and write.

Last updated: September 19, 2026

If you take anticoagulants, blood pressure medication, or immunosuppressants, or have an autoimmune condition, talk to your healthcare provider before using reishi rather than relying on this overview alone.

---

References

Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. *Cochrane Database of Systematic Reviews*. 2016;4:CD007731. PubMed: 27045603

Li X, Sun L, Chimonas S, Li SQ, Wang Y. Symptom improvements and adverse effects with Reishi mushroom use: A cross-sectional survey of cancer patients. *Integrative Medicine Research*. 2024;13(4):101089. PubMed: 27511742

NIH LiverTox. Lingzhi, Reishi. National Institute of Diabetes and Digestive and Kidney Diseases. Last updated October 5, 2024. NIH

Guedikian R, Kim B, Singh G, Alexander R. Ganoderma lingzhi (Reishi Mushroom)-Induced Acute Liver Injury in the Setting of Alcohol Use. *Cureus*. 2023;15(9):e45953. PubMed: 37885515

ACG 2025. S5705 Acute Liver Injury Associated With Reishi Mushroom Supplementation in a Patient on Chronic Acetaminophen Therapy. *American Journal of Gastroenterology*. 2025;120(10S2). Link

Wanmuang H, et al. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. *J Med Assoc Thai*. 2007;90(1):179-181. PubMed: 17621752

Melek Arsoy HE, Özdemir Ö. Acute neurotoxicity in a child following multi-component medicinal fungi supplementation. *BMC Complement Med Ther*. 2026;26:130. PubMed: 42063068

Melek Arsoy HE, Ozdemir O. Acute neurotoxicity in a child following multi-component medicinal fungi exposure. *BMC Complementary Medicine and Therapies*. 2026;26(1).

Ahmad R, Riaz M, Khan A, et al. Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties. *Phytotherapy Research*. 2021;35(11):6030-6062.

Merck Manual Professional Edition. Reishi. Full review July 2025. Merck

Memorial Sloan Kettering Cancer Center. Reishi Mushroom. Integrative Medicine monograph. 2024. MSKCC

Lam CS, et al. Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review. *Chinese Medicine*. 2020;15:75. PubMed: 32724333

Tsai CC, Yang FL, Huang ZY, et al. Oligosaccharide and peptidoglycan of Ganoderma lucidum activate the immune response in human mononuclear cells. *Journal of Agricultural and Food Chemistry*. 2012;60(11):2830-2837. PubMed: 22364151

Ha do T, Oh J, Khoi NM, et al. In vitro and in vivo hepatoprotective effect of ganodermanontriol against carbon tetrachloride-induced liver injury. *Journal of Ethnopharmacology*. 2013;150(3):875-885. PubMed: 24140584

Teschke R. Idiosyncratic Hepatocellular Drug-Induced Liver Injury: Mechanisms and Susceptibility. *Biomedicines*. 2024;12(10). PubMed: 39457521

References